BC-based Kardium has secured $340 million CAD (approximately $250 million USD) to support the global launch of its flagship product: the Globe Pulsed Field System, a device designed to treat atrial fibrillation (AF).
The funding will fuel regulatory approval, manufacturing scale-up, and commercial expansion, particularly in the U.S. and Europe.
New and existing backers support aggressive rollout plans
The round was led by Janus Henderson Investors and the Qatar Investment Authority, with participation from existing investors like T. Rowe Price, Fidelity, and a major strategic player. The company previously raised $143 million CAD in 2023.
Advertisement
Atrial fibrillation treatment poised for innovation
The Globe System features a 122-electrode catheter that combines mapping and pulsed field ablation to streamline AF procedures. With U.S. FDA approval expected later this year, Kardium plans to expand operations across North America and Europe. CEO Kevin Chaplin suggests a public offering could follow as early as 2026.
